Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthriti...
October 02 2019 - 9:00AM
Flexion Therapeutics (Nasdaq:FLXN) is teaming up with Chris
Dickerson, a former New York Yankees outfielder and member of the
2011 and 2012 playoff teams, to raise awareness of the impact of
osteoarthritis (OA). Introduced at the start of baseball’s
postseason, the awareness effort highlights Chris’ journey as a
professional athlete and parent living with OA knee pain. A
degenerative joint disease, OA affects more than 30 million adults
living in the U.S. and accounts for more than $185 billion in
annual expenditures.
With their first playoff game set for this week, Chris’ former
teammates in New York are battling a record number of injuries,
including many involving debilitating knee pain. Chris, 37, was
first diagnosed with OA at 21 following a decade of his own sports
injuries. Despite six knee surgeries and numerous treatments over
the course of his career, he played professional baseball for 15
years and spent seven seasons as a major league outfielder with the
Yankees, Cincinnati Reds, Milwaukee Brewers, Baltimore Orioles and
Cleveland Indians. Chris retired in 2017 to pursue a career with a
sports technology company and conduct broadcasting
work.
“I know exactly what players with arthritis are feeling at this
point in the long season, especially when you have to prepare
mentally and physically for the playoffs,” Chris said. “When you
develop OA of the knee, you are told to expect pain to be a
constant in your life. It hinders your work performance no matter
your profession and your ability to enjoy activities that many take
for granted. My 2 ½ year-old-daughter is just discovering the joy
of riding a bicycle. It has been challenging for me to keep up with
her with a smile on my face because of my persistent knee pain.
Just walking a few blocks in Manhattan to participate in work
meetings can be a challenge.”
He continued: “When I was competing professionally in baseball,
I was always open to researching and trying different treatments
because I had to play through the constant knee pain to earn a
living. Now in my post-playing days, I was fortunate to have the
opportunity to meet a leading orthopedic surgeon, who provided me
with a thorough assessment of my options and created a treatment
plan to address my OA of the knee.”
Chris added, “OA knee pain might not seem catastrophic, but for
those who have it there is a constant battle that drastically
affects one’s quality of life. I am proud to raise awareness of
this painful, progressive and incurable disease.”
Click here to view Chris’ story.
About Osteoarthritis (OA) of the Knee
OA, also known as degenerative joint disease, affects more than
30 million adults living in the U.S. and accounts for more than
$185 billion in annual expenditures. In 2016, more than 15 million
Americans were diagnosed with OA of the knee and the average age of
physician-diagnosed knee OA has fallen by 16 years, from 72 in the
1990s to 56 in the 2010s. The prevalence of OA is expected to
continue to increase as a result of aging, obesity and sports
injuries. Each year approximately five million OA patients receive
either an immediate-release corticosteroid or hyaluronic acid
intra-articular injection to manage their knee pain.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical
company focused on the development and commercialization of novel,
local therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis, a type of degenerative
arthritis. The company's core values are focus, ingenuity,
tenacity, transparency and fun. For the past three years, Flexion
has been named one of the Best Places to Work by the Boston
Business Journal, and Flexion was also recognized as a Top Place to
Work in Massachusetts by The Boston Globe in 2017 and 2018. Visit
flexiontherapeutics.com.
Contacts:
Scott YoungFlexion Therapeutics, Inc.T:
781-305-7194syoung@flexiontherapeutics.com
Nic Johnson or Scott StachowiakRusso Partners Sports-Health
AllianceT: (212) 845-4242T: (646)
942-5630njohnson@russopartnersllc.comsstachowiak@russopartnersllc.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b6e5b7e0-ecce-4a7c-a9c7-0ca159775d38
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2023 to Apr 2024